Home > Publications Database > Omega-3 Blood Levels and Stroke Risk: A Pooled and Harmonized Analysis of 183 291 Participants From 29 Prospective Studies. > print

001     266761
005     20240403113329.0
024 7 _ |a pmc:PMC10840378
|2 pmc
024 7 _ |a 10.1161/STROKEAHA.123.044281
|2 doi
024 7 _ |a pmid:38134264
|2 pmid
024 7 _ |a 0039-2499
|2 ISSN
024 7 _ |a 1524-4628
|2 ISSN
024 7 _ |a altmetric:157725337
|2 altmetric
037 _ _ |a DZNE-2024-00024
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a O'Keefe, James H
|0 0000-0002-3376-5822
|b 0
245 _ _ |a Omega-3 Blood Levels and Stroke Risk: A Pooled and Harmonized Analysis of 183 291 Participants From 29 Prospective Studies.
260 _ _ |a Philadelphia, Pa.
|c 2024
|b Lippincott Williams & Wilkins
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1705486344_18421
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The effect of marine omega-3 PUFAs on risk of stroke remains unclear.We investigated the associations between circulating and tissue omega-3 PUFA levels and incident stroke (total, ischemic, and hemorrhagic) in 29 international prospective cohorts. Each site conducted a de novo individual-level analysis using a prespecified analytical protocol with defined exposures, covariates, analytical methods, and outcomes; the harmonized data from the studies were then centrally pooled. Multivariable-adjusted HRs and 95% CIs across omega-3 PUFA quintiles were computed for each stroke outcome.Among 183 291 study participants, there were 10 561 total strokes, 8220 ischemic strokes, and 1142 hemorrhagic strokes recorded over a median of 14.3 years follow-up. For eicosapentaenoic acid, comparing quintile 5 (Q5, highest) with quintile 1 (Q1, lowest), total stroke incidence was 17% lower (HR, 0.83 [CI, 0.76-0.91]; P<0.0001), and ischemic stroke was 18% lower (HR, 0.82 [CI, 0.74-0.91]; P<0.0001). For docosahexaenoic acid, comparing Q5 with Q1, there was a 12% lower incidence of total stroke (HR, 0.88 [CI, 0.81-0.96]; P=0.0001) and a 14% lower incidence of ischemic stroke (HR, 0.86 [CI, 0.78-0.95]; P=0.0001). Neither eicosapentaenoic acid nor docosahexaenoic acid was associated with a risk for hemorrhagic stroke. These associations were not modified by either baseline history of AF or prevalent CVD.Higher omega-3 PUFA levels are associated with lower risks of total and ischemic stroke but have no association with hemorrhagic stroke.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a atrial fibrillation
|2 Other
650 _ 7 |a cerebrovascular disease
|2 Other
650 _ 7 |a fish
|2 Other
650 _ 7 |a fish oil
|2 Other
650 _ 7 |a stroke
|2 Other
650 _ 7 |a Eicosapentaenoic Acid
|0 AAN7QOV9EA
|2 NLM Chemicals
650 _ 7 |a Docosahexaenoic Acids
|0 25167-62-8
|2 NLM Chemicals
650 _ 7 |a Fatty Acids, Omega-3
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Prospective Studies
|2 MeSH
650 _ 2 |a Eicosapentaenoic Acid
|2 MeSH
650 _ 2 |a Docosahexaenoic Acids
|2 MeSH
650 _ 2 |a Hemorrhagic Stroke: epidemiology
|2 MeSH
650 _ 2 |a Fatty Acids, Omega-3
|2 MeSH
650 _ 2 |a Stroke: epidemiology
|2 MeSH
650 _ 2 |a Ischemic Stroke
|2 MeSH
650 _ 2 |a Risk Factors
|2 MeSH
700 1 _ |a Tintle, Nathan L
|b 1
700 1 _ |a Harris, William S
|b 2
700 1 _ |a O'Keefe, Evan L
|0 0000-0002-2746-2323
|b 3
700 1 _ |a Sala-Vila, Aleix
|b 4
700 1 _ |a Attia, John
|0 0000-0001-9800-1308
|b 5
700 1 _ |a Garg, G Manohar
|0 0000-0003-0514-0865
|b 6
700 1 _ |a Hure, Alexis
|0 0000-0003-2225-0986
|b 7
700 1 _ |a Bork, Christian Sørensen
|0 0000-0001-5233-2902
|b 8
700 1 _ |a Schmidt, Erik Berg
|0 0000-0002-0623-5666
|b 9
700 1 _ |a Venø, Stine Krogh
|b 10
700 1 _ |a Chien, Kuo-Liong
|0 0000-0003-4979-8351
|b 11
700 1 _ |a Chen, Yun-Yu Amelia
|0 0000-0001-7009-7838
|b 12
700 1 _ |a Egert, Sarah
|b 13
700 1 _ |a Feldreich, Tobias Rudholm
|b 14
700 1 _ |a Ärnlöv, Johan
|0 0000-0002-6933-4637
|b 15
700 1 _ |a Lind, Lars
|0 0000-0003-2335-8542
|b 16
700 1 _ |a Forouhi, Nita G
|0 0000-0002-5041-248X
|b 17
700 1 _ |a Geleijnse, Johanna M
|0 0000-0001-7638-0589
|b 18
700 1 _ |a Pertiwi, Kamalita
|0 0000-0003-2861-9051
|b 19
700 1 _ |a Imamura, Fumiaki
|0 0000-0002-6841-8396
|b 20
700 1 _ |a de Mello Laaksonen, Vanessa
|0 0000-0003-3414-6983
|b 21
700 1 _ |a Uusitupa, W Matti
|0 0000-0001-6052-2001
|b 22
700 1 _ |a Tuomilehto, Jaakko
|0 0000-0002-3424-0745
|b 23
700 1 _ |a Laakso, Markku
|0 0000-0002-3394-7749
|b 24
700 1 _ |a Lankinen, Maria Anneli
|0 0000-0002-9158-283X
|b 25
700 1 _ |a Laurin, Danielle
|0 0000-0001-5032-2452
|b 26
700 1 _ |a Carmichael, Pierre-Hugues
|0 0000-0002-5324-862X
|b 27
700 1 _ |a Lindsay, Joan
|b 28
700 1 _ |a Leander, Karin
|0 0000-0002-1404-9222
|b 29
700 1 _ |a Laguzzi, Federica
|0 0000-0003-3551-1348
|b 30
700 1 _ |a Swenson, Brenton R
|0 0000-0002-4176-8273
|b 31
700 1 _ |a Longstreth, William T
|b 32
700 1 _ |a Manson, JoAnn E
|0 0000-0002-9426-7595
|b 33
700 1 _ |a Mora, Samia
|0 0000-0001-6283-0980
|b 34
700 1 _ |a Cook, Nancy R
|0 0000-0002-9705-0842
|b 35
700 1 _ |a Marklund, Matti
|0 0000-0002-3320-796X
|b 36
700 1 _ |a Melo van Lent, Debora
|0 P:(DE-2719)2811697
|b 37
700 1 _ |a Murphy, Rachel
|0 0000-0003-4383-5641
|b 38
700 1 _ |a Gudnason, Vilmundur
|0 0000-0001-5696-0084
|b 39
700 1 _ |a Ninomiya, Toshihara
|b 40
700 1 _ |a Hirakawa, Yoichiro
|b 41
700 1 _ |a Qian, Frank
|0 0000-0002-5579-3410
|b 42
700 1 _ |a Sun, Qi
|0 0000-0002-8480-1563
|b 43
700 1 _ |a Hu, Frank
|0 0000-0002-8233-6274
|b 44
700 1 _ |a Ardisson Korat, Andres V
|0 0000-0003-4599-2245
|b 45
700 1 _ |a Risérus, Ulf
|0 0000-0002-8620-4586
|b 46
700 1 _ |a Lázaro, Iolanda
|0 0000-0002-6172-9845
|b 47
700 1 _ |a Samieri, Cecilia
|b 48
700 1 _ |a Le Goff, Mélanie
|0 0000-0003-2848-6287
|b 49
700 1 _ |a Helmer, Catherine
|b 50
700 1 _ |a Steur, Marinka
|0 0000-0002-9028-0290
|b 51
700 1 _ |a Voortman, Trudy
|0 0000-0003-2830-6813
|b 52
700 1 _ |a Ikram, M Kamran
|0 0000-0003-0173-9571
|b 53
700 1 _ |a Tanaka, Toshiko
|b 54
700 1 _ |a Das, Jayanta K
|b 55
700 1 _ |a Ferrucci, Luigi
|0 0000-0002-6273-1613
|b 56
700 1 _ |a Bandinelli, Stefania
|b 57
700 1 _ |a Tsai, Michael
|0 0000-0001-7553-3408
|b 58
700 1 _ |a Guan, Weihua
|0 0000-0002-0956-9821
|b 59
700 1 _ |a Garg, Parveen
|0 0000-0002-6482-2711
|b 60
700 1 _ |a Verschuren, W M Monique
|0 0000-0003-2134-4227
|b 61
700 1 _ |a Boer, Jolanda M A
|0 0000-0002-9714-4304
|b 62
700 1 _ |a Biokstra, Anneke
|0 0009-0001-2062-8810
|b 63
700 1 _ |a Virtanen, Jyrki
|0 0000-0002-0648-999X
|b 64
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 65
700 1 _ |a Westra, Jason
|b 66
700 1 _ |a Albuisson, Luc
|b 67
700 1 _ |a Yamagishi, Kazumasa
|0 0000-0003-3301-5519
|b 68
700 1 _ |a Siscovick, David S
|0 0000-0003-0461-175X
|b 69
700 1 _ |a Lemaitre, Rozenn N
|0 0000-0002-7038-1844
|b 70
700 1 _ |a Mozaffarian, Dariush
|0 0000-0001-7958-9492
|b 71
773 _ _ |a 10.1161/STROKEAHA.123.044281
|g Vol. 55, no. 1, p. 50 - 58
|0 PERI:(DE-600)1467823-8
|n 1
|p 50 - 58
|t Stroke
|v 55
|y 2024
|x 0039-2499
856 4 _ |u https://pub.dzne.de/record/266761/files/DZNE-2024-00024_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/266761/files/DZNE-2024-00024_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |o oai:pub.dzne.de:266761
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 65
|6 P:(DE-2719)2000057
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2024
915 _ _ |a Allianz-Lizenz
|0 StatID:(DE-HGF)0410
|2 StatID
|d 2023-08-25
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b STROKE : 2022
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-08-25
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-08-25
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-08-25
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b STROKE : 2022
|d 2023-08-25
920 1 _ |0 I:(DE-2719)1011201
|k AG Wagner
|l Neuropsychology
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1011201
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21